KJIM
The Korean Journal of Internal Medicine Korean J Intern Med
1226-3303
2005-6648
The Korean Association of Internal Medicine
10.3904/kjim.2020.549.e1
kjim-2020-549-e1
Erratum
Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma
Jung Jae-Woo 1 *
Park Hae-Sim 2 *
Park Choon-Sik 3
Cho Sang-Heon 4
Choi Inseon S. 5
Moon Hee-Bom 6
Kwon Soon Seog 7
Yoon Ho Joo 8
Park Jung Won 9
Lee Jong-Myung 10
Choi Dong-Chull 11
Choi Byoung Whui 1 12
1 Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea
2 Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea
3 Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
4 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
5 Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea
6 Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
7 Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea
8 Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea
9 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
10 Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea
11 Division of Allergy, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
12 Department of Internal Medicine, Chung-Ang University H.C.S. Hyundae Hospital, Namyangju, Korea
9
2021
1
9
2021
36
5
1260
1260
Copyright © 2021 The Korean Association of Internal Medicine
2021
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ ) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
In the article cited above, there was an error in Figure 3B . A corrected version of Figure 3B is attached.
We apologize for any inconvenience that this may have caused.
Figures
Figure 3. Korean asthma control test (K-ACT) at week 0, 16, and 24. (A) Mean ± standard error of the mean K-ACT. (B) Asthma control levels. K-ACT was improved after omalizumab treatment, and the proportions of “partly controlled” and “controlled” on week 16 and week 24 were higher than those at week 0. a p < 0.001, b p < 0.005 compared to K-ACT at week 0.
![]()